Accepted for Publication: January 16, 2023.
Published Online: March 15, 2023. doi:10.1001/jamadermatol.2023.0127
Corresponding Author: John M. Kirkwood, MD, University of Pittsburgh, School of Medicine, Melanoma & Skin Cancer Disease Program, UPMC Hillman Cancer Center, UPMC Hillman Cancer Center, 5117 Centre Ave, Ste 1.32, Pittsburgh, PA 15213 (firstname.lastname@example.org).
Author Contributions: Dr Kirkwood had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Kashani-Sabet, Leachman, and Stein contributed equally to the writing of the manuscript.
Concept and design: Kirkwood, Kashani-Sabet, Leachman, Stein, Arbiser, Grant-Kels, Nelson, Tsao, Karapetyan, Savory, Sondak.
Acquisition, analysis, or interpretation of data: Kirkwood, Kashani-Sabet, Leachman, Stein, Berry, Celebi, Curiel-Lewandrowski, MD, Ferris, Grant-Kels, Grossman, Kulkarni, Marchetti, Polsky, Seiverling, Swetter, Tsao, Verdieck-Devlaeminck, Wei, Bar, Bartlett, Bolognia, Bowles, Cha, Chu, Hartman, Hawryluk, Jampel, Kheterpal, Lawson, Leming, Liebman, Ming, Sahni, Shaikh, Sober, Sondak, Spaccarelli, Usatine, Venna.
Drafting of the manuscript: Kirkwood, Kashani-Sabet, Leachman, Stein, Arbiser, Seiverling, Tsao, Verdieck-Devlaeminck, Karapetyan, Sahni.
Critical revision of the manuscript for important intellectual content: Kirkwood, Kashani-Sabet, Leachman, Stein, Arbiser, Berry, Celebi, Curiel-Lewandrowski, MD, Ferris, Grant-Kels, Grossman, Kulkarni, Marchetti, Nelson, Polsky, Seiverling, Swetter, Tsao, Wei, Bar, Bartlett, Bolognia, Bowles, Cha, Chu, Hartman, Hawryluk, Jampel, Karapetyan, Kheterpal, Lawson, Leming, Liebman, Ming, Sahni, Savory, Shaikh, Sober, Sondak, Spaccarelli, Usatine, Venna.
Obtained funding: Kirkwood.
Administrative, technical, or material support: Kirkwood, Leachman, Arbiser, Curiel-Lewandrowski, MD, Grant-Kels, Nelson, Bolognia, Bowles, Lawson, Sahni, Shaikh.
Supervision: Kirkwood, Kashani-Sabet, Leachman, Arbiser, Grant-Kels, Tsao, Kheterpal.
Other - participated in creating the data: Sober.
Conflict of Interest Disclosures: Dr Kirkwood reported grants from DermTech Inc outside the submitted work. Dr Kashani-Sabet reported stock in Melanoma Diagnostics, ownership interest in DNARX LLC, a patent issued for molecular classification of melanoma, and advisory board service for Bristol-Myers Squibb outside the submitted work. Dr Leachman reported honorarium from the Melanoma Research Foundation during the conduct of the study and research support from Castle Biosciences, Sklip Inc, Orlucent Inc, MAB, and VeriSkin Inc outside the submitted work. Dr Stein reported financial support from MoleSafe USA during the conduct of the study. Dr Berry reported personal fees from Melanoma Research Alliance during the conduct of the study as well as personal fees from Bristol Myers Squibb and Barco Inc outside the submitted work. Dr Celebi reported personal fees from NYU Grossman School of Medicine during the conduct of the study. Dr Curiel-Lewandrowski reports grants from Amgen outside the submitted work. Dr Ferris reported personal fees and grants from Derm Tech and grants from Castle Biosciences outside the submitted work. Dr Grossman reported research support from Derm Tech, Orlucent Inc, and Skin Analytics and personal fees from Orlucent Inc outside the submitted work. Dr Seiverling reported personal fees from DermaSensor Consultant for image quality review outside the submitted work. Dr Wei reported personal fees from Merck outside the submitted work. Dr Bar reported research support from Castle and personal fees from Regeneron during the conduct of the study and outside the submitted work. Dr Bartlett reported grants from SkylineDx and personal fees from Excite International LLC outside the submitted work. Dr Bolognia reported royalties from Elsevier outside the submitted work. Dr Bowles reported research support from Genentech, Amgen, Replimune, and Natera outside the submitted work. Dr Hartman reported grants from DermaSensor outside the submitted work. Dr Hawryluk reported being an author and reviewer for UpToDate outside the submitted work. Dr Savory reported being a board member for the Texas Dermatological Society. Dr Sondak reported personal fees from AMLo Biosciences, Alkermes, Bristol Myers Squibb, Genesis Drug Discovery & Development, Iovance, Merck, Novartis, Regeneron, and Ultimovacs; grants from Neogene Therapeutics and Turnstone; and nonfinancial support from SkylineDX outside the submitted work. No other disclosures were reported.
Funding/Support: The funding for the administration and facilitation of the consensus development conference and the development of thismanuscript was provided by Dermtech Inc in an unrestricted award that was administratively overseen by the Melanoma Research Foundation and managed and executed at UPMC by the principal investigato (Dr Kirkwood). DermTech was not involved in the preparation or editing of the manuscript.
Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
JF , Youlden
DR , Baade
PD , Soyer
HP , Green
AC , Smithers
BM . Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014. Int J Cancer
. 2018;142(8):1528-1535. doi:10.1002/ijc.31141
MM , Leachman
SA , Aspinwall
et al. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag
. 2017;4(1):13-37. doi:10.2217/mmt-2016-0022
RI , Xue
Y , Singer
S , Markossian
TW , Joyce
C , Mostaghimi
A . Modelling the value of risk-stratified skin cancer screening of asymptomatic patients by dermatologists. Br J Dermatol
. 2020;183(3):509-515. doi:10.1111/bjd.18816
D , Flaherty
KT , Duncan
LM , Kashani-Sabet
M , Ugurel
S . Biomarkers for melanoma. In: Balch
C , ed. Cutaneous Melanoma
. 6th ed. Springer Nature Switzerland; 2019. doi:10.1007/978-3-319-46029-1_45-1
JG , Barnhill
RL , Elder
et al. Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ
. 2017;357:j2813. doi:10.1136/bmj.j2813
SA , Pham
AK , Dagrosa
et al. Concordance analysis of the 23-gene expression signature (myPath Melanoma) with fluorescence in situ hybridization assay and single nucleotide polymorphism array in the analysis of challenging melanocytic lesions: results from an academic medical center. Am J Dermatopathol
. 2020;42(12):939-947. doi:10.1097/DAD.0000000000001713
International Agency for Research on Cancer Working Group on Artificial Ultraviolet Light and Skin Cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int J Cancer
. 2007;120(5):1116-1122. PubMedGoogle Scholar
RF , Newton Bishop
JA , Bergman
W , Tucker
MA . Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol
. 1999;17(10):3245-3251. doi:10.1200/JCO.19220.127.116.1145
CB , Orlow
I , Hummer
et al; Genes Environment and Melanoma Study Group. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst
. 2005;97(20):1507-1515. doi:10.1093/jnci/dji312
JL , Cunningham
K , Silverman
R , Madan
E , Nguyen
BM . Case-control study of tumor stage-dependent outcomes for cutaneous squamous cell carcinoma in immunosuppressed and immunocompetent patients. Dermatol Surg
. 2019;45(12):1467-1476. doi:10.1097/DSS.0000000000001930
DE , Bastian
BC , Cree
IA , Massi
D , Scolyer
RA . The 2018 World Health Organization classification of cutaneous, mucosal, and uveal Melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med
. 2020;144(4):500-522. doi:10.5858/arpa.2019-0561-RA
BN , Covington
KR , Kurley
et al. Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients. J Am Acad Dermatol
. 2020;83(3):745-753. doi:10.1016/j.jaad.2020.03.053
SS , Yang
X , Fortman
et al. A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma. J Am Acad Dermatol
. 2022;87(4):906-908, 22, 00798-8. doi:10.1016/j.jaad.2022.05.008
I , Tempel
D , Dwarkasing
et al. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary. Eur J Surg Oncol
. 2022;48(2):320-325. doi:10.1016/j.ejso.2021.11.010